Industries

• Reset all ×
• Life Sciences ×
• 2021 ×

Showing 261–270 of 279 results

Sort by popularity Sort by average rating Sort by latest Sort by price: low to high Sort by price: high to low

• 

  ADCs for HER2-Expressing Breast Cancer Market in China 2021

  The ADCs for HER2-expressing breast cancer market in China in terms of revenue is set to grow by US$ 373 million during 2021-2027, growing at a compound annual growth rate (CAGR) of 96.8% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the ADCs for HER2-expressing breast cancer market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

  USD 450
• 

  Urothelial Carcinoma (UC) Drug Market in China 2021

  The urothelial carcinoma (UC) drug market in China in terms of revenue is set to grow by US$ 1 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 27.6% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the urothelial carcinoma (UC) drug market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

  USD 450
• 

  Gastric Cancer Drug Market in China 2021

  The gastric cancer drug market in China in terms of revenue is set to grow by US$ 4 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 10.3% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the gastric cancer drug market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

  USD 450
• 

  Autoimmune Diseases Treatment Market in China 2021

  The autoimmune diseases treatment market in China in terms of revenue is set to grow by US$ 11 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 27% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the autoimmune diseases treatment market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

  USD 450
• 

  Chimeric Antigen Receptor (CAR) T-Cell Therapy Market in China 2021

  In terms of revenue, the chimeric antigen receptor (CAR) T-cell therapy market in China is projected to grow at a compound annual growth rate (CAGR) of 17% over the analysis period of 2021 to 2027, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the chimeric antigen receptor (CAR) T-cell therapy market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

  USD 450
• 

  Myelodysplastic Syndromes (MDS) Drug Market in China 2021

  The myelodysplastic syndromes (MDS) drug market in China in terms of revenue is set to grow by US$ 548 million during 2021-2027, growing at a compound annual growth rate (CAGR) of 17.3% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the myelodysplastic syndromes (MDS) drug market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

  USD 450
• 

  Non-Small Cell Lung Cancer (NSCLC) Drug Market in China 2021

  The non-small cell lung cancer (NSCLC) drug market in China in terms of revenue is set to grow by US$ 13 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 17.1% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the non-small cell lung cancer (NSCLC) drug market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

  USD 450
• 

  Hepatocellular Carcinoma (HCC) Drug Market in China 2021

  The hepatocellular carcinoma (HCC) drug market in China in terms of revenue is set to grow by US$ 4 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 21.7% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the hepatocellular carcinoma (HCC) drug market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

  USD 450
• 

  Diffuse Large B Cell Lymphomas (DLBCL) Drug Market in China 2021

  The diffuse large B cell lymphomas (DLBCL) drug market in China in terms of revenue is set to grow by US$ 3 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 22.2% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the diffuse large B cell lymphomas (DLBCL) drug market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

  USD 450
• 

  Multiple Myeloma Drug Market in China 2021

  The multiple myeloma drug market in China in terms of revenue is set to grow by US$ 2 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 18.8% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the multiple myeloma drug market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

  USD 450